Dyslipidemia
Conditions
Interventions
Intervention group:Lactobacillus plantarum granules , once a day, 1 bag (1 g) each time (contains 1.2 billion cfu of viable bacteria), take with warm water (less than 37 degrees), lifestyle guidance
Control group:Placebo (maltodextrin) gradules, once a day, 1 bag (1 g)each time, take with warm water (less than 37 degrees), lifestyle guidance.
Sponsors
Xi’an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-70 years; 2. 3.4 = LDL-C<4.9 mmol/L, 5.18 = TC<7.2 mmol/L, and 1.7 = TG<5.6 mmol/L; 3. They did not use lipid-lowering drugs, or they took lipid-lowering drugs and stopped taking them for more than 3 months.
Exclusion criteria
Exclusion criteria: 1. Those who cannot eat by mouth or take the test sample as required; 2. The principal complaint is unclear; 3. Pregnant or lactating women, pregnant women; 4. Allergic constitution or allergy to the test sample; 5. ASCVD risk is assessed as high risk (ASCVD risk is assessed according to the assessment form of Guidelines for the Prevention and Treatment of Dyslipidemia in Chinese Adults (2016 Revision)) *; 6. Those who have undergone digestive system surgery within 30 days are currently or within 30 days receiving antibiotic treatment (except for skin or reproductive tract drugs); 7. Inpatients or those with acute gastrointestinal diseases within 2 weeks; 8. Patients with serious diseases and mental disorders such as heart, liver, kidney and hematopoietic system; 9. Those who regularly take probiotic products within 30 days, and have taken drugs (including but not limited to phytosterol, berberine, Monacolin K) that affect blood lipid within 2 weeks, affect the judgment of the results; 10. Abnormal liver and kidney function; Suffering from diseases that affect blood lipid metabolism (including but not limited to thyroid diseases, biliary diseases, pancreatitis and immune disorders); Severe hyperacidity (including but not limited to regular administration of H2 receptor blockers, proton pump inhibitors and other antacid drugs within 2 weeks); Severe constipation (including but not limited to regular use of laxatives such as loperamide within 2 weeks); 11. Those who fail to take interventions as required during the induction period and cannot comply; 12. Less than 30 years old and there is evidence that there is a tendency of hereditary hyperlipidemia; 13. Other patients considered by the investigator not suitable for the study; 14. Those who do not sign the informed consent form.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Serum total cholesterol (TC);High-density lipoprotein cholesterol (HDL-C);Triglycerides (TG);Glucose;Insulin;BMI;The diversity and abundance of intestinal flora (16S); | — |
Primary
| Measure | Time frame |
|---|---|
| Serum Low Density Lipoprotein Cholesterol (LDL-C); | — |
Countries
China
Contacts
Public ContactXin Lin
Xi’an Jiaotong University
Outcome results
None listed